Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Non-Current Assets (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Other Non-Current Assets for 5 consecutive years, with $929000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets changed N/A year-over-year to $929000.0, compared with a TTM value of $929000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $881000.0, changed 0.11% over the prior year.
  • Other Non-Current Assets was $929000.0 for Q3 2025 at Barinthus Biotherapeutics, up from $902000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.1 million in Q3 2023 and bottomed at $719000.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $900285.7, with a median of $893500.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets soared 30.46% in 2023, then fell 13.91% in 2024.
  • Year by year, Other Non-Current Assets stood at $804000.0 in 2021, then increased by 21.39% to $976000.0 in 2022, then dropped by 9.63% to $882000.0 in 2023, then fell by 0.11% to $881000.0 in 2024, then grew by 5.45% to $929000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for BRNS at $929000.0 in Q3 2025, $902000.0 in Q1 2025, and $881000.0 in Q4 2024.